MTOR and breast carcinoma: Despite the absence of SCRIB mutations in clinical breast cancer, over-expression resulting from amplifications in its gene or other mechanisms may increase the cytoplasmic localization of the protein and activate the PI3K/AKT/mTOR pathway.